Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

NCT03048422 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

643

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Dolutegravir
DRUG: Emtricitabine/tenofovir alafenamide
DRUG: Emtricitabine/tenofovir disoproxil fumarate
DRUG: Efavirenz/emtricitabine/tenofovir disoproxil fumarate

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)